Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

Inclusion Criteria: * Subject capable of understanding instructions and giving her consent for participation. * Diagnosis of COPD or chronic bronchitis without obstruction due to biomass smoke exposure: 1. Diagnosis of COPD according to GOLD guidelines 2023 with: \>100 hours-year of biomass exposure index, and with a post-bronchodilator spirometry FEV1 \> 70% of predicted value. 2. Diagnosis of Chronic Bronchitis without obstruction with at least \>100 hours-year of biomass smoke exposure index or more than 10 years of continued exposure to biomass smoke, and with 1) antecedent of chronic bronchitis, and 2) post-bronchodilator spirometry FEV1/FVC \>0.7. * Able to attend all visits. * Cooperative patients with adequate understanding and skill in using inhalers, or with caregivers capable of administering medications and filling out a daily symptom diary. * Stable patients, with no history of exacerbations in the last 4 weeks before inclusion. Exclusion Criteria: * Pregnancy or in the breastfeeding period. * Documented allergy or intolerance to any of the study medications. * History of clinically significant bronchiectasis, tuberculosis, recent respiratory infection (4 weeks), or cardiovascular comorbidity that contraindicates pulmonary function tests or that influences their status and functional class. * Patients with suspicion or history of cancer. * Uncontrolled diseases: acute hyperthyroidism, acute uncontrolled DM2, acid-peptic disease that causes bleeding, uncontrolled hematological diseases, etc. In general, any decompensated disease that, in the opinion of the principal investigator, may influence the results of the study.